Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancerLin Zhao, Jia Wang, Yuanyuan Liu et al.|Cell Death and Disease|2022Cited by 110
Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsyRui Chen, Yinghao Sun, Liping Xie et al.|Urologic Oncology Seminars and Original Investigations|2016Cited by 37
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter studyKaili Yang, Yunbo Zhao, Lu Han et al.|Cancer Immunology Immunotherapy|2021Cited by 30
Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancerNing Jia, Chunmei Bai, Lianpeng Chang et al.|BMC Cancer|2021Cited by 6
Regorafenib plus PD-1 inhibitors in Chinese patients with microsatellite stable/mismatch repair proficient metastatic colorectal cancer: A real-world study.Kaili Yang, Lin Zhao, Yunbo Zhao et al.|Journal of Clinical Oncology|2021Cited by 1